Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience-Reference-Cited by-同舟云学术

Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience

Published:1996-11 Issue:9 Volume:7 Page:933-938
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Vignetti M.,Orsini E.,Petti M.C.,Moleti M.L.,Andrizzi C.,Pinto R.M.,Amadori S.,Meloni G.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/7/9/933/446805/7-9-933.pdf

Reference31 articles.

1. Comparison of three remission induction regimens and two post-induction strategies for the treatment of acute nonlymphocytic leukemia: A Cancer and Leukemia Group B study;Preisler;Blood,1987

2. High-dose cytarabine and daunorubicin induction and post-remission chemotherapy for the treatment of acute myelogenous leukemia in adult;Phillips;Blood,1991

3. for the MRC Adult Leukemia Working Party. The practicability of the comparison of intensive chemotherapy alone or with additional allo or auto BMT for adult AML: Progress in MRC tenth trial;Burnett;Haematologica,1991

4. Intensive chemotherapy with or without additional bone marrow transplantation in paediatric AML: Progress report on the MRC AML10 trial;Stevens;Leukemia,1992

5. Therapy of acute myeloid leukemia: Where from now?;Mandelli,1993

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of the Association Between TET2 Expression and Response to CAPE;International Journal of Hematology and Oncology;2021-07-31

2. MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia;European Journal of Haematology;2020-04-07

3. Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year single-center experience;Clinics;2020

4. Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review;Annals of Hematology;2018-04-21

5. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2017-12